BCR signaling plays a central pathogenic role in CLL,17 with its importance underscored by current therapeutics such as Bruton tyrosine kinase inhibitors, which induce remission and improve patient survival.18 This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.